ARE · Q1 2026 Earnings

Narrative arc: Q2 FY2025 cautious operating quarter → Q3 FY2025 broad capitulation across guidance, capital plan, dividend → Q4 FY2025 multi-year reset with $1.45B impairment and 45% dividend cut → Q1 FY2026 structural impairment in public biotech demand with renewal book repricing negative.

Three quarters ago Joel Marcus framed the cycle as "fourth year of a life science bear market" with line-of-sight to recovery. Q4 FY2025 extended that to "fifth year" while pushing recovery 4–5 years further out. This quarter the language jumps a category: "This is maybe the first quarter in the history of the company that I can remember where we didn't sign a single public biotech lease." When a 30-year operator invokes the company's history to describe demand collapse in a 24%-of-ARR segment, that's not cyclical commentary — it's a structural diagnosis with no operating-era precedent.

The tone on AI completed an inversion that's been building for a year. Earlier quarters did not feature AI as a discrete risk; this quarter management was forced to address it head-on and chose maximum agnosticism: AI "can support but not replace physical experimentation" and "most experts believe that AI will have a small impact on real estate requirements and could even see the need for additional dry and wet space." This is a REIT acknowledging it cannot underwrite whether its core asset class is a beneficiary or a victim of the dominant industrial technology shift.

The development pipeline pivoted from defensive curtailment to category abandonment. Q3 FY2025 introduced the willingness to stop capitalizing interest mid-project; Q4 FY2025 booked $1.45B of impairments and put four more projects under review. This quarter the framing shifts again: "For both 311 Arsenal Street and 3000 Minuteman Road, if we complete these advanced technology leases, we may place all or some portion of these spaces into the operating pool... will reduce our capital needs and generate near-term revenue upon delivery." Two named lab-development properties are now potential homes for "advanced technology" — a tenant category ARE has historically not pursued and which the bull case never priced. In Q&A Marcus described the leasing progress as "breadcrumbs" — incremental wins in a tenant category the company does not yet have proof points in.

Capital recycling logic inverted within a single quarter. Q4 FY2025 telegraphed an aggressive $2.9B-midpoint disposition program weighted to non-core assets including vacant space. This quarter management is now holding some vacant assets pending leasing momentum: "we ended up changing some of the assumptions to other assets that have more kind of stabilized occupancy." Translation: assets management thought it could sell vacant at acceptable prices aren't moving, so the program is rotating toward stabilized assets that buyers actually want — which means the marginal disposition is more dilutive to retained portfolio NOI than the prior plan implied.

The 2027 expiration disclosure is the new overhang. Management flagged 1.5M sq ft of 2027 lease expirations ($97M annual rent) expected to have "material downtime." 2027 was the year management had pointed to in prior quarters as the recovery period — now it's flagged as the next vacancy cliff. The wind-down reserve was also raised from $23M to $25–30M to absorb additional private and public biotech failures.